[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cybrexa Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100540334","phase-2-a-study-of-cbx-12-in-subjects-with-platinum-resistant-or-refractory-ovarian-cancer-100540334",false,"NCT06315491","A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer","A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer","Inclusion Criteria:\n\n* Subjects must have histologically- or cytologically-diagnosed epithelial high-grade serous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer that is refractory to prior therapy and must have platinum-resistant disease defined as:\n\n  * Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring ≤ 26 weeks after their last dose of platinum.\n  * Patients who have progressed following a second course of a platinum based regimen.\n  * Subjects may have up to 2 additional systemic regimens for advanced or metastatic disease. Maintenance regimens (e.g., with a PARP inhibitor or bevacizumab) are not considered separate regimens.\n* Age greater than or equal to 18 years at the time of signing the informed consent form (ICF).\n* Has measurable disease per RECIST 1.1.\n* Has provided written informed consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate liver, renal, hematologic, pulmonary and coagulation function.\n\nExclusion Criteria:\n\n* Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12.\n* Subjects who are currently receiving any other anticancer or investigational agent(s).\n* Clinically significant intercurrent disease.\n* Active human immunodeficiency virus (HIV) infection.\n* Active hepatitis B or C infection.","FEMALE","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg\u002Fm2 every 21 days or 100 mg\u002Fm2 every 21 days.",[26,27],"Platinum-resistant Ovarian Cancer","Refractory Ovarian Carcinoma","RECRUITING","2025-10-02",{"date":31,"type":32},"2025-10-06","ACTUAL",{"date":34,"type":32},"2024-09-25",{"date":36,"type":20},"2025-10",{"name":38,"class":39},"Cybrexa Therapeutics","INDUSTRY",17,""]